KRAS and neoplasm: KRAS mutations play a pivotal role in orchestrating an immunosuppressive tumor microenvironment by promoting the pathological recruitment of Tregs, MDSCs, and tumor-associated neutrophils via the upregulation of cytokine and chemokine expression (117, 124, 126, 127, 129).